ProTrials Research INC and Calithera Biosciences, Inc. have entered an agreement to further develop treatments for cancer.
According to the agreement, ProTrials Research will be responsible to provide a clinical trial developmental programme for Calithera Biosciences’ first-in-class inhibitor product CB-839 to target glutaminase enzyme in tumour metabolism.
Bristol-Myers Squibb has entered a clinical research agreement with Janssen Biotech, Inc. to evaluate the combination of the former’s immune-Oncology (I-O) agent Opdivo (nivolumab) and the latter’s Live Attenuated Double-Deleted (LADD), listerial monocytogenes cancer immunotherapy expressing mesothelin and EGFRvIII (JNJ-64041757) in patients with non-small-cell lung cancer (NSCLC).
According to the agreement, the phase II clinical trial to evaluate the tolerability and clinical activity of the combination of two immune oncology compounds will be conducted by Janssen Biotech.
Espada Dermatology has acquired the GlyDerm line of skin care products from Lautus Pharmaceuticals LLC, allowing the company to offer GlyDerm skincare products.
Lumosa Therapeutics plans to raise gross proceeds of $14.53m through the public offering of 8.5 million of its common stock shares.
The company plans to use the funds to increase the working capital and enrich the operating funds.
Tricida INC has raised gross proceeds of $55m in a series C financing round.
The financing round was led by Longitute Capital Management Co LLC along with Vivo Capital LLC, Orbimed Advisors LLC, Sibling Capital Ventures and Limulus Ventures Partners LP, and SidleyAustin LLP acted as legal advisor to the offering.
The company plans to use the funds to conduct late-stage trials of the clinical candidate TRC101 in patients with kidney disease.
Image: Bristol-Myers Squibb has entered a clinical research agreement with Janssen Biotech. Photo: Courtesy of Bic.